The 4-year risk of CDP did not differ between treatment groups; however, patients treated with rituximab had a higher chance of CDI, aligned with previous findings.19 Serum NfL, a biomarker of axonal damage and acute inflammation,21 did not differ significantly between the treatment groups in our study. The gene discussed is NEFL; the disease is clostridium difficile infection.